MISSISSAUGA, ON, May 10, 2018 /PRNewswire/ - Nuvo
Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF)
a commercial healthcare company with a portfolio of commercial
products and pharmaceutical manufacturing capabilities, today
announced that at its 2018 Annual and Special Meeting of
Shareholders held on May 10, 2018 in
Mississauga, all nominees listed
in the management proxy circular dated March
29, 2018 were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
Daniel
Chicoine
|
5,006,478
|
270,092
|
94.88
|
5.12
|
David A.
Copeland
|
5,024,433
|
252,137
|
95.22
|
4.78
|
Anthony E.
Dobranowski
|
5,022,434
|
254,136
|
95.18
|
4.82
|
Robert
Harris
|
5,185,721
|
90,849
|
98.28
|
1.72
|
John C.
London
|
5,020,389
|
256,181
|
95.14
|
4.86
|
Dr. Jacques
Messier
|
5,024,075
|
252,495
|
95.21
|
4.79
|
About Nuvo Pharmaceuticals
Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a global commercial
healthcare company with a portfolio of commercial products and
pharmaceutical manufacturing capabilities. Nuvo has four commercial
products that are available in a number of countries:
Pennsaid® 2%, Pennsaid, Resultz® and the
heated lidocaine/tetracaine patch. Nuvo manufactures Pennsaid 2%
for the U.S market, Pennsaid for the global market and the bulk
drug product for the HLT Patch at its FDA, Health Canada and E.U.
approved manufacturing facility in Varennes, Québec. The Company's focus is
to maximize the value of Pennsaid 2% and Resultz through
out-licensing to commercial partners in international markets and
identifying new opportunities to acquire additional,
revenue-generating or late-stage products or businesses to further
diversify the Company's existing product portfolio. For additional
information, please visit www.nuvopharmaceuticals.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-announces-director-election-results-of-its-annual-general-meeting-300646763.html
SOURCE Nuvo Pharmaceuticals Inc.